Foundation Fighting Blindness Celebrates Bennett, Maguire, and High's Breakthrough Prize for Revolutionary Gene Therapy
11-05-2026 | 4 Min.
2020 Llura Liggett Gund Award recipient honored for pioneering gene therapy that transformed vision research
Atsena Therapeutics Advances to Pivotal Phase 3 Trial for X-Linked Retinoschisis
21-04-2026 | 3 Min.
Data monitoring committee recommends proceeding with registration-enabling study for ATSN-201
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
16-04-2026 | 3 Min.
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) by Foundation Fighting Blindness
Opus Genetics Secures $155 Million Financing to Accelerate Gene Therapy Pipeline
08-04-2026 | 2 Min.
Strategic funding extends cash runway through 2029 and advances multiple inherited retinal disease programs
VeonGen Reports Promising Clinical Progress for Stargardt Disease Gene Therapy
26-03-2026 | 2 Min.
VG801 shows sustained vision improvements through 12 months with favorable safety profile
The Foundation Fighting Blindness is the driving force in the global development of treatments and cures for blinding diseases. To learn more, go to FightingBlindness.org.